Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA(1c), disease duration and treatment intensity: results from the CANVAS Program

AIMS/HYPOTHESIS: Type 2 diabetes mellitus can manifest over a broad clinical range, although there is no clear consensus on the categorisation of disease complexity. We assessed the effects of canagliflozin, compared with placebo, on cardiovascular and kidney outcomes in the CANagliflozin cardioVasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Tamara K., Li, Jing-Wei, Kang, Amy, Heerspink, Hiddo J. L., Hockham, Carinna, Arnott, Clare, Neuen, Brendon L., Zoungas, Sophia, Mahaffey, Kenneth W., Perkovic, Vlado, de Zeeuw, Dick, Fulcher, Greg, Neal, Bruce, Jardine, Meg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494676/
https://www.ncbi.nlm.nih.gov/pubmed/34448033
http://dx.doi.org/10.1007/s00125-021-05524-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494676/
https://www.ncbi.nlm.nih.gov/pubmed/34448033
http://dx.doi.org/10.1007/s00125-021-05524-1

Ejemplares similares